Adaptive Biotechnologies Corporation
NASDAQ:ADPTBiotechnology
+$0.61 today
- Market cap
- $4.61B
- Beta
- 2.15
- P/E (TTM)
- -54.5
- EPS (TTM)
- -$0.32
Volume 2.21M
Average 1.94M
ADPT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Adaptive Biotechnologies CorporationNASDAQ: ADPT
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development declines year over year
Q2 FY2026 research & development of $19.15M fell 20.6% year over year, behind the -7.8% change in trailing-twelve-month research & development. Sequentially, it fell 18.9% from the prior quarter. Over 3 fiscal years it compounded at -12.9% a year.
Context
- Research & development amounted to 33.9% of revenue in FY2025, down 23.7 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -20.6% toward the trailing-twelve-month pace of -7.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 93.77M USD
- Year-over-year change
- -8.9%
- 4-year CAGR
- -9.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 93.77M | -8.9% |
| FY2024 | 2024-12-31 | 102.95M | -15.7% |
| FY2023 | 2023-12-31 | 122.12M | -13.9% |
| FY2022 | 2022-12-31 | 141.76M | -0.4% |
| FY2021 | 2021-12-31 | 142.34M | — |
Research & Development vs competitors
How ADPT compares with its peers on the latest reported figures
- ADPT's LTM Jun 2026 research & development of $88.21M is the 9th highest of the 10 companies compared; the peer median is $236.92M.
- Its year-over-year change of -7.8% is the 8th highest of 10, against a peer median of +3.2%.
- Research & development amounts to 28.6% of revenue for ADPT, versus a peer median of 52.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $408.66M | +3.1% | +9.5% | 261.9% | |
| LTM Sep 2026 | $378.58M | -9.4% | +7.3% | 27.9% | |
| LTM Mar 2026 | $339.54M | +5.2% | +52.0% | 150.7% | |
| LTM Jun 2026 | $301.59M | +72.6% | +71.3% | — | |
| LTM Jun 2026 | $236.92M | +3.2% | -8.3% | 52.7% | |
| LTM Sep 2026 | $211.05M | -0.0% | +18.8% | 37026.5% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $183.14M | +22.7% | +72.2% | — |
| LTM Sep 2026 | $115.59M | +83.0% | +14.7% | 16.9% | |
| LTM Jun 2026 | $88.21M | -7.8% | -12.9% | 28.6% | |
| LTM Mar 2026 | $11.48M | -17.7% | -13.7% | 1.9% | |
| Peer median (excluding ADPT) | $236.92M | +3.2% | +14.7% | 52.7% | |
Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 154.34M | 185.31M | 170.28M | 178.96M | 276.98M |
| Cost of Revenue | 49.3M | 57.91M | 75.55M | 72.08M | 71.36M |
| Gross Profit | 105.04M | 127.4M | 94.72M | 106.88M | 205.62M |
| Gross Margin | 68.1% | 68.7% | 55.6% | 59.7% | 74.2% |
| Research & Development | 142.34M | 141.76M | 122.12M | 102.95M | 93.77M |
| Selling, General & Admin | 169.97M | 184.13M | 172.51M | 157.57M | 167.27M |
| Operating Expenses | 314.01M | 327.59M | 321.76M | 269.43M | 262.74M |
| Depreciation & Amortization | 13.95M | 20.92M | 22.23M | 19.26M | 17.83M |
| EBITDA | (193.35M) | (175.21M) | (189.27M) | (128.76M) | (29.85M) |
| EBITDA Margin | -125.3% | -94.6% | -111.2% | -71.9% | -10.8% |
| Operating Income | (208.97M) | (200.19M) | (227.04M) | (162.55M) | (57.12M) |
| Operating Margin | -135.4% | -108.0% | -133.3% | -90.8% | -20.6% |
| Interest Income | 1.67M | 4.06M | 15.53M | 14.53M | 9.44M |
| Interest Expense | 0 | 4.24M | 13.8M | 11.58M | 11.78M |
| Other Income / Expenses | 1.67M | (182K) | 1.73M | 2.95M | (2.33M) |
| Income Before Tax | (207.3M) | (200.37M) | (225.3M) | (159.6M) | (59.46M) |
| Pre-Tax Margin | -134.3% | -108.1% | -132.3% | -89.2% | -21.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (207.28M) | (200.19M) | (225.25M) | (159.49M) | (59.5M) |
| Net Margin | -134.3% | -108.0% | -132.3% | -89.1% | -21.5% |
| EPS (Basic) | (1.46) | (1.00) | (1.56) | (1.08) | (0.39) |
| EPS (Diluted) | (1.46) | (1.00) | (1.56) | (1.08) | (0.39) |
| Weighted Avg Shares | 140.35M | 142.52M | 144.38M | 147.1M | 151.72M |
| Weighted Avg Shares (Diluted) | 140.35M | 142.52M | 144.38M | 147.1M | 151.72M |
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
Intrinsic Alpha fair value
Locked
Current Price
$28.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.